§Why CasetextPricing

Sepracor Inc. v. Dey LP et al

REPLY BRIEF re MOTION to Consolidate Cases

4 Cited authorities

  1. Aventis Pharma Deutschland v. Cobalt Pharmaceuts

    355 F. Supp. 2d 586 (D. Mass. 2005)   Cited 14 times
    Holding no inducement where proposed labeling did not include instructions for infringing uses

  2. Section 355 - New drugs

    21 U.S.C. § 355   Cited 2,252 times   341 Legal Analyses
    Granting the court discretion to change the date on which an ANDA may be approved if "either party to the action failed to reasonably cooperate in expediting the action"

  3. Section 253 - Disclaimer

    35 U.S.C. § 253   Cited 180 times   37 Legal Analyses
    Granting patentee authority to disclaim issued or pending claims

  4. Section 1.321 - Statutory disclaimers, including terminal disclaimers

    37 C.F.R. § 1.321   Cited 75 times   33 Legal Analyses
    Incorporating the language of § 253